These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
230 related articles for article (PubMed ID: 19243307)
1. Ten years of rituximab in NHL. Winter MC; Hancock BW Expert Opin Drug Saf; 2009 Mar; 8(2):223-35. PubMed ID: 19243307 [TBL] [Abstract][Full Text] [Related]
3. Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study. Palanca-Wessels MC; Czuczman M; Salles G; Assouline S; Sehn LH; Flinn I; Patel MR; Sangha R; Hagenbeek A; Advani R; Tilly H; Casasnovas O; Press OW; Yalamanchili S; Kahn R; Dere RC; Lu D; Jones S; Jones C; Chu YW; Morschhauser F Lancet Oncol; 2015 Jun; 16(6):704-15. PubMed ID: 25925619 [TBL] [Abstract][Full Text] [Related]
4. Spotlight on rituximab in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Cvetković RS; Perry CM BioDrugs; 2006; 20(4):253-7. PubMed ID: 16831024 [TBL] [Abstract][Full Text] [Related]
5. Rituximab therapy for indolent non-Hodgkin's lymphoma. Hagenbeek A; Czuczman MS; Ghielmini M; Herold M; Kimby E; Solal-Céligny P; Unterhalt M Anticancer Drugs; 2002 Nov; 13 Suppl 2():S11-7. PubMed ID: 12710586 [TBL] [Abstract][Full Text] [Related]
6. Mechanism of action of rituximab. Cerny T; Borisch B; Introna M; Johnson P; Rose AL Anticancer Drugs; 2002 Nov; 13 Suppl 2():S3-10. PubMed ID: 12710585 [TBL] [Abstract][Full Text] [Related]
7. Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma. Fanale MA; Younes A Drugs; 2007; 67(3):333-50. PubMed ID: 17335294 [TBL] [Abstract][Full Text] [Related]
9. The therapeutic use of rituximab in non-Hodgkin's lymphoma. Marcus R; Hagenbeek A Eur J Haematol Suppl; 2007 Jan; (67):5-14. PubMed ID: 17206982 [TBL] [Abstract][Full Text] [Related]
10. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Cvetković RS; Perry CM Drugs; 2006; 66(6):791-820. PubMed ID: 16706552 [TBL] [Abstract][Full Text] [Related]
11. Monoclonal antibodies for the treatment of hematologic malignancies: clinical trials in Japan. Tobinai K Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S90-6. PubMed ID: 12819934 [TBL] [Abstract][Full Text] [Related]
13. A molecular perspective on rituximab: A monoclonal antibody for B cell non Hodgkin lymphoma and other affections. Seyfizadeh N; Seyfizadeh N; Hasenkamp J; Huerta-Yepez S Crit Rev Oncol Hematol; 2016 Jan; 97():275-90. PubMed ID: 26443686 [TBL] [Abstract][Full Text] [Related]
18. Targeting CD20 in follicular NHL: novel anti-CD20 therapies, antibody engineering, and the use of radioimmunoconjugates. Leonard JP Hematology Am Soc Hematol Educ Program; 2005; ():335-9. PubMed ID: 16304400 [TBL] [Abstract][Full Text] [Related]
19. Rituximab: an innovative therapy for non-Hodgkin's lymphoma. Wood AM Am J Health Syst Pharm; 2001 Feb; 58(3):215-29; quiz 230-2. PubMed ID: 11217177 [TBL] [Abstract][Full Text] [Related]
20. Clinical trials of a mouse-human chimeric anti-CD20 monoclonal antibody (rituximab) for B cell non-Hodgkin's lymphoma in Japan. Tobinai K Cancer Chemother Pharmacol; 2001 Aug; 48 Suppl 1():S85-90. PubMed ID: 11587374 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]